The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown. OBJECTIVE: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI regimens. DATA SOURCES: A PubMed search through July 18, 2016, using the following keywords was performed: "ipilimumab," "MDX-010," "nivolumab," "BMS-963558," "pembrolizumab," "MK-3475," "atezolizumab," "MPDL3280A," and "phase." STUDY SELECTION: Thirty-eight randomized clinical trials evaluating the usage of these ICIs for treatment of advanced solid tumors were identified, resulting in a total of 7551 patients who were eligible for a meta-analysis. Regimens were categorized by class into monotherapy with a PD-1 (programmed cell death protein 1) inhibitor, a CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) inhibitor, or a PD-L1 (programmed cell death 1 ligand 1) inhibitor, and combination therapy with PD-1 plus CTLA-4 inhibitors. DATA EXTRACTION AND SYNTHESIS: The data were extracted by 1 primary reviewer (R.B.-S.) and then independently reviewed by 2 secondary reviewers (W.T.B. and A.C.G.-C.) following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Inferences on the incidence of AEs were made using log-odds random effects models. MAIN OUTCOMES AND MEASURES: Incidence of all-grade hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, and insulin-deficient diabetes. RESULTS: Overall, 38 randomized clinical trials comprising 7551 patients were included in this systematic review and meta-analysis. The incidence of both hypothyroidism and hyperthyroidism was highest in patients receiving combination therapy. Patients on the combination regimen were significantly more likely to experience hypothyroidism (odds ratio [OR], 3.81; 95% CI, 2.10-6.91, P < .001) and hyperthyroidism (OR, 4.27; 95% CI, 2.05-8.90; P = .001) than patients on ipilimumab. Compared with patients on ipilimumab, those on PD-1 inhibitors had a higher risk of developing hypothyroidism (OR, 1.89; 95% CI, 1.17-3.05; P = .03). The risk of hyperthyroidism, but not hypothyroidism, was significantly greater with PD-1 than with PD-L1 inhibitors (OR, 5.36; 95% CI, 2.04-14.08; P = .002). While patients who received PD-1 inhibitors were significantly less likely to experience hypophysitis than those receiving ipilimumab (OR, 0.29; 95% CI, 0.18-0.49; P < .001), those who received combination therapy were significantly more likely to develop it (OR, 2.2; 95% CI, 1.39-3.60; P = .001). For primary adrenal insufficiency and insulin-deficient diabetes no statistical inferences were made due to the smaller number of events. CONCLUSIONS AND RELEVANCE: Our study provides more precise data on the incidence of endocrine dysfunctions among patients receiving ICI regimens. Patients on combination therapy are at increased risk of thyroid dysfunction and hypophysitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The occurrence of AI in ICI users has been reported in about 1% of cases and more frequently in individuals receiving combination regimens like anti-CTLA4 plus anti-PD1/PD-L1 agents (4%-8%) (25, 28, 29).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While hypothyroidism and thyrotoxicosis have been mainly associated with anti-PD1/PDL1 agents (especially in a combination regimen with anti-CTLA4, co-occurring with hepatobiliary and respiratory irAEs), hypophysitis, AI, and hypopituitarism were more frequently reported with anti-CTLA4 drugs (ipilimumab) (25, 26).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ICI-diabetes is an insulin-deficient phenotype that presents as acute severe hyperglycemia or DKA and appears to occur more abruptly than type 1 diabetes (216-218).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint inhibitors (ICIs) (agents that block programmed cell death protein 1 [PD-1] and programmed cell death protein ligand 1 [PD-L1]) suppress physiologic blocks on immune responses, which can result in autoimmune toxicities, including autoimmune diabetes (incidence approximately #1%).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Flagged first, then by citations
1 of the 67 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
Cited by
Sorted by citations
Items 201–300 of 1,000
Gauci, M.-L., Boudou, P., Baroudjian, B., Vidal-Trécan, T., Meda, L. D., Madelaine, I., Basset‐Séguin, N., Bagot, M., Pagès, C., Mourah, S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2178-0 · Cited by 36
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 40
Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40
Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors
Venetsanaki, V., Boutis, A. L., Chrisoulidou, A., & Papakotoulas, P. (2019) · Current Oncology · doi:10.3747/co.26.4151 · Cited by 35
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
Hakami, O. A., Ioana, J., Ahmad, S., Tun, T. K., Sreenan, S., & McDermott, J. H. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0153 · Cited by 35
Chen, X., Lu, Y., Yu, H., Du, K., Zhang, Y., Yang, N., & Huang, Q. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1982494 · Cited by 34
McDermott, M. T. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202004070 · Cited by 35
Cooksley, T., Girotra, M., Ginex, P., Gordon, R. A., Anderson, R., Blidner, A. G., Choi, J. N., Dougan, M. L., Glezerman, I. G., Gupta, D., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05709-1 · Cited by 34
Yoo, W. S., Ku, E. J., Lee, E. K., & Ahn, H. Y. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1785 · Cited by 35
Iatrogenic adrenal insufficiency in adults
Martin‐Grace, J., Tomkins, M., O’Reilly, M., & Sherlock, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00929-x · Cited by 35
Sbardella, E., Tenuta, M., Sirgiovanni, G., Gianfrilli, D., Pozza, C., Venneri, M. A., Cortesi, E., Marchetti, P., Lenzi, A., Gelibter, A. J., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14135 · Cited by 34
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33
Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
Iadarola, C., Croce, L., Quaquarini, E., Teragni, C., Pinto, S., Bernardo, A., Fonte, R., Marinò, M., Rotondi, M., & Chiovato, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00813 · Cited by 33
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 39
Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus
Liao, D., Liu, C., Chen, S., Liu, F., Li, W., Shangguan, D., & Shi, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110414 · Cited by 35
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1589374 · Cited by 35
Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
Kawkgi, O. M. E., Li, D., Kotwal, A., & Wermers, R. A. (2020) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.07.006 · Cited by 33
Testosterone deficiency in men receiving immunotherapy for malignant melanoma
Peters, M., Pearlman, A. M., Terry, W. W., Mott, S. L., & Monga, V. (2021) · Oncotarget · doi:10.18632/oncotarget.27876 · Cited by 33
Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
Manz, S., Losa, M., Fritsch, R., & Scharl, M. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002018 · Cited by 36
Wu, L., Xu, Y., Wang, X., Cheng, X., Zhang, Y., Wang, Y., Fan, X., Zhao, H., Liu, H., Chai, X., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03323-9 · Cited by 33
Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma
Abikhair, M., Roudiani, N., Chen, J., Santana, A. L., Doudican, N. A., Proby, C. M., Felsen, D., & Carucci, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.120750 · Cited by 33
Immune checkpoint inhibitor–associated hypercalcaemia
Izzedine, H., Chazal, T., Wanchoo, R., & Jhaveri, K. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa326 · Cited by 32
Martella, S., Lucas, M. W., Porcu, M., Perra, L., Denaro, N., Pretta, A., Deias, G., Willard-Gallo, K. E., Parra, H. J. S., Saba, L., et al. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.003 · Cited by 32
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
Tzoulis, P., Corbett, R., Ponnampalam, S., Baker, E., Heaton, D., Doulgeraki, T., & Stebbing, J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0111 · Cited by 32
Thyroid Sequelae of Pediatric Cancer Therapy
Waguespack, S. G. (2018) · Hormone Research in Paediatrics · doi:10.1159/000495040 · Cited by 31
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy
Atkinson, M. A., & Lansdown, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101635 · Cited by 32
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 39
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
Yamauchi, I., & Yabe, D. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0328 · Cited by 35
Diabetes mellitus induced by immune checkpoint inhibitors
Zheng, Z., Liu, Y., Yang, J., Tan, C., Zhou, L., Wang, X., Li, X., Zhang, S., Chen, Y., & Liu, X. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3366 · Cited by 32
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Okura, N., Asano, M., Uchino, J., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., Fukui, M., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072033 · Cited by 32
Peravali, M., Gomes-Lima, C. J., Tefera, E. A., Baker, M., Sherchan, M., Farid, S., Burman, K. D., Constantinescu, F., & Veytsman, I. G. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i2.103 · Cited by 31
Ando, H., Suzuki, K., & Yanagihara, T. (2021) · Biomedicines · doi:10.3390/biomedicines9101484 · Cited by 31
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Zhang, Y., Zhang, X., Li, W., Du, Y., Hu, W., & Zhao, J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2018894 · Cited by 33
Labadzhyan, A., Wentzel, K. P., Hamid, O., Chow, K., Kim, S., Piro, L. D., & Melmed, S. K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac161 · Cited by 31
The management and metabolic characterization: hyperthyroidism and hypothyroidism
Wang, Y., Sun, Y., Yang, B., Wang, Q., & Kuang, H. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102308 · Cited by 34
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30
Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction
Zhang, Q., Jiao, X., & Lai, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad260 · Cited by 31
Guerrero, E. P., Johnson, D. B., Bachelot, A., Lebrun‐Vignes, B., Moslehi, J. J., & Salem, J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.002 · Cited by 31
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Olsson-Brown, A. C., Lord, R., Sacco, J. J., Wagg, J., Coles, M. C., & Pirmohamed, M. (2020) · Endocrine Connections · doi:10.1530/ec-19-0473 · Cited by 32
Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma
Huppert, L. A., Gordan, J. D., & Kelley, R. K. (2020) · Clinical Liver Disease · doi:10.1002/cld.879 · Cited by 30
Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Deligiorgi, M. V., Siasos, G., Vergadis, C., & Trafalis, D. T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106427 · Cited by 30
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors
Nakano-Tateno, T., Lau, K. J., Wang, J. Z., McMahon, C., Kawakami, Y., Tateno, T., & Araki, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624686 · Cited by 30
Managing side effects of immune checkpoint inhibitors in breast cancer
Criscitiello, C., Corti, C., Pravettoni, G., & Curigliano, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103354 · Cited by 33
Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
Wang, D., Gu, Y., Yan, X., Huo, C.-D., Wang, G., Zhao, Y., Teng, M., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844260 · Cited by 30
Baek, H.-S., Jeong, C., Shin, K., Lee, J., Suh, H., Lim, D., Kang, M. I., & Ha, J. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01004-8 · Cited by 30
Ullur, A. R., Côté, G., Pelletier, K., & Kitchlu, A. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad014 · Cited by 30
Immunotherapies for advanced hepatocellular carcinoma
Sun, L., Zhang, K.-J., Xie, Y.-M., Liu, J., & Xiao, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138493 · Cited by 29
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Linsley, P. S., & Long, S. A. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000488 · Cited by 30
Immune checkpoints: new insights into the pathogenesis of thyroid eye disease
Shu, X., Shao, Y., Chen, Y., Zeng, C., Huang, X., & Wei, R.-L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392956 · Cited by 30
Arecco, L., Leite, L. D. M., Gentile, G., Janković, K., Stana, M., Ottonello, S., Scavone, G., Spinaci, S., & Lambertini, M. (2025) · Human Reproduction · doi:10.1093/humrep/deaf096 · Cited by 33
Endocrine sequelae of immune checkpoint inhibitors
Ntali, G., Kassi, E. N., & Alevizaki, M. K. (2017) · HORMONES · doi:10.14310/horm.2002.1754 · Cited by 29
Yuen, K. C. J., POPOVIC, V. M., & Trainer, P. J. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.010 · Cited by 29
Manojlović-Gačić, E., Bollerslev, J., & Casar‐Borota, O. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12568 · Cited by 29
Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma
Agarwal, K., Yousaf, N., & Morganstein, D. L. (2020) · Clinical Medicine · doi:10.7861/clinmed.2018-0440 · Cited by 29
Shi, Y., Shen, M., Zheng, X., & Yang, T. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.09.016 · Cited by 29
Yamamoto, N., Nakanishi, Y., Gemma, A., Nakagawa, K., Sakamoto, T., Akamatsu, A., & Ohe, Y. (2021) · Cancer Science · doi:10.1111/cas.15117 · Cited by 29
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 32
The science of vaccine safety: Summary of meeting at Wellcome Trust
Plotkin, S. A., Offit, P. A., Destefano, F. R., Larson, H. J., Arora, N. K., ZUBER, P. L. F., Fombonne, E. J., Sejvar, J. J., Lambert, P. H., Hviid, A. P., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.024 · Cited by 31
Endocrine Late Effects in Childhood Cancer Survivors
Casano, P., & Izurieta‐Pacheco, A. C. (2022) · Cancers · doi:10.3390/cancers14112630 · Cited by 28
Sepsis and Adrenal Insufficiency
Fowler, C., Raoof, N. D., & Pastores, S. M. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231183396 · Cited by 30
Liu, Y., Chen, W., Ruan, R., Zhang, Z., Wang, Z., Guan, T., Lin, Q., Tang, W., Deng, J., Wang, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05262-z · Cited by 33
Eochagáin, C. M., Neuendorff, N. R., Gente, K., Leipe, J., Verhaert, M., Sam, C., de Glas, N. A., Kadambi, S. M., Canin, B. E., Gomes, F., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00404-2 · Cited by 28
Rochefoucauld, J. D. L., Noël, N., & Lambotte, O. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02295-2 · Cited by 30
Isolated anterior pituitary dysfunction in adulthood
Prencipe, N., Marinelli, L., Varaldo, E., Cuboni, D., Berton, A. M., Bioletto, F., Bona, C., Gasco, V., & Grottoli, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1100007 · Cited by 28
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
Terrin, M., Migliorisi, G., Buono, A. D., Gabbiadini, R., Mastrorocco, E., Quadarella, A., Repici, A., Santoro, A., & Armuzzi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411504 · Cited by 30
Andrade, M. D. O., Gutierres, I. G., Tavares, M. C., de Sousa, I. M., Balint, F. C., Comini, A. C. M., Gouveia, M. C., Bines, J., Madasi, F., Ferreira, R. D. P., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104473 · Cited by 29
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27
Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
Alessandrino, F., Shah, H., & Ramaiya, N. H. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2017.12.014 · Cited by 27
Type 1 diabetes induced by immune checkpoint inhibitors
Zhang, R., Cai, X., Liu, L., Han, X., & Ji, L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000972 · Cited by 27
Balibegloo, M., Nejadghaderi, S. A., Sadeghalvad, M., Soleymanitabar, A., Nezamabadi, S. S., Saghazadeh, A., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107796 · Cited by 27
Shalit, A., Sarantis, P., Koustas, E., Trifylli, E.-M., Matthaios, D., & Karamouzis, M. V. (2023) · Cancers · doi:10.3390/cancers15020375 · Cited by 29
Endocrine toxicity of cancer immunotherapy: clinical challenges
Anderson, B., & Morganstein, D. L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0489 · Cited by 26
Servetto, A., Salomone, F., Costanzo, F. D., Iuliano, R., Marandino, L., Napolitano, F., Santaniello, A., Placido, P. D., Placido, S. D., Maïo, M. D., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103649 · Cited by 26
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28
Samoa, R. A., Lee, H. S., Kil, S. H., & Roep, B. O. (2020) · Diabetes Care · doi:10.2337/dc20-0740 · Cited by 27
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology
Kim, A. E., Nelson, A. A., Stimpert, K., Flyckt, R. L., Thirumavalavan, N., Baker, K., Weinmann, S. C., & Hoimes, C. J. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00469 · Cited by 26
Immune checkpoint inhibitors and endocrine side effects, a narrative review
Agrawal, L., Bacal, A., Jain, S., Singh, V., Emanuele, N. V., Emanuele, M. A., & Meah, F. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1709344 · Cited by 26
A Novel Etiology of Hypophysitis
Fernandes, S., Varlamov, E. V., McCartney, S., & Fleseriu, M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.002 · Cited by 25
Shi, Y., Shen, M., Zheng, X., Chen, Y., Zhao, R., Gu, Y., & Yang, T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa553 · Cited by 25
Leiter, A., Carroll, E., Brooks, D., Shimol, J. B., Eisenberg, E., Wisnivesky, J. P., Galsky, M. D., & Gallagher, E. J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108633 · Cited by 26
Takayasu, S., Mizushiri, S., Watanuki, Y., Yamagata, S., Usutani, M., Nakada, Y., Asari, Y., Murasawa, S., Kageyama, K., & Daimon, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-05400-x · Cited by 25
Tsukamoto, T., & Miki, Y. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01407-0 · Cited by 25
Sheikhbahaei, S., Marcus, C. V., Sadaghiani, M. S., Rowe, S. P., Pomper, M. G., & Solnes, L. B. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26538 · Cited by 24
Wu, L., Carlino, M. S., Brown, D. A., Long, G. V., Clifton-Bligh, R. J., Mellor, R., Moore, K., Sasson, S. C., Menzies, A. M., Tsang, V., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad685 · Cited by 26
Davies, M. J. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.11 · Cited by 26
Park, H., Hatabu, H., Ricciuti, B., Aijazi, S. J., Awad, M. M., & Nishino, M. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109275 · Cited by 24
Labella, M., & Castells, M. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.008 · Cited by 24
Ashi, S. I. A., Thapa, B., Flores, M., Ahmed, R., Rahim, S. E. G., Amir, M., Alomari, M., Chadalavada, P. N., Morrison, S. L., Bena, J., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab100 · Cited by 25
Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient’s Perspective
Claessen, K. M. J. A., Andela, C. D., Biermasz, N. R., & Pereira, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701365 · Cited by 25
Yoshino, T., André, T., Kim, T. W., Yong, W. P., Shiu, K., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., García‐Carbonero, R., et al. (2022) · Cancer Science · doi:10.1111/cas.15650 · Cited by 23
Kambhampati, S., Gray, L., Fakhri, B., Lo, M., Vu, K., Arora, S., Kaplan, L., Ai, W. Z., & Andreadis, C. B. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.014 · Cited by 24
Aguilar-Salinas, C. A., Renner, A., Rojas, C., Samtani, S., & Burotto, M. (2020) · Case Reports in Oncology · doi:10.1159/000507652 · Cited by 24
Patel, N. S., Oury, A., Daniels, G. A., Bazhenova, L., & Patel, S. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0375 · Cited by 25
Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
Ho, A. K., Ho, A. M. ‐., Cooksley, T., Nguyen, G., Erb, J., & Mizubuti, G. B. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005029 · Cited by 24
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
Turchini, J., Sioson, L., Clarkson, A., Sheen, A., & Gill, A. J. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09673-2 · Cited by 24
Garmes, H. M., Boguszewski, C. L., Miranda, P. A. C., Martins, M. R. A., Correa‐Silva, S. R., Abucham, J., Musolino, N. R. D. C., Vilar, L., Portari, L. H. C., Gadelha, M. R., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000335 · Cited by 23
Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
Zhang, A. L., Wang, F., Chang, L., McDonnell, M. E., & Min, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.620522 · Cited by 23
Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab
Irani, A. Z., Almuwais, A., & Gibbons, H. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-245846 · Cited by 25
Metadata
- Authors
- Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Tolaney, Sara M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 173
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC5838579
- OpenAlex
- W2760410509
- Cited by
- 1,115
- References
- 67
- Citations by year
- 2026: 113 · 2025: 134 · 2024: 116 · 2023: 138 · 2022: 173 · 2021: 150 · 2020: 150 · 2019: 93 · 2018: 46
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- endocrine adverse events, immune checkpoint inhibitors, hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, insulin-deficient diabetes, PD-1 inhibitors, CTLA-4 inhibitors, PD-L1 inhibitors, combination immunotherapy, ipilimumab, nivolumab, pembrolizumab, atezolizumab, advanced solid tumors, adverse event incidence, randomized controlled trials
- MeSH terms
- Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Endocrine System Diseases, Endocrine Glands, Humans, Immunotherapy, Neoplasms, Incidence, Randomized Controlled Trials as Topic, Protein Kinase Inhibitors, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
